Articles from RyCarma Therapeutics, Inc.

RyCarma Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class small molecule therapeutics for skeletal muscle diseases, today announced that the first patient was dosed in a Phase 2 clinical trial of surlorian in patients with RYR1-related myopathy (RYR1-RM).

RyCarma Therapeutics, Inc., a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases, has appointed Elizabeth Tarka, M.D., as its Chief Medical Officer (CMO). In this role, Dr. Tarka will lead the clinical development of surlorian (ARM210) as it advances into Phase 2 trials for heart failure with reduced ejection fraction (HFrEF) and ryanodine receptor 1-related myopathies (RYR1-RM).

RyCarma Therapeutics, Inc., formerly known as ARMGO Pharma (the “Company” or “RyCarma”), a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases, today unveiled its new leadership and company name change from “ARMGO Pharma, Inc.” to “RyCarma Therapeutics, Inc.” and introduced a new program in heart failure. The name RyCarma references the Company’s foundational work and leadership in ryanodine receptor (RyR) biology and in establishing the therapeutic potential of Rycals®, a novel class of small molecule drugs. RyCarma’s new program focuses on developing its lead candidate ARM210 in heart failure with reduced ejection fraction, which affects millions of people worldwide. ARM210 is also currently being investigated in ryanodine receptor 1-related myopathies (RYR1-RM), a group of rare neuromuscular diseases caused by mutations in the RYR1 gene.